Gheorghe L, Brouwer J, Mathijssen H, et al. - In a cohort of 366 patients who underwent transfemoral transcatheter aortic valve implantation (TAVI), researchers compared a novel collagen-based MANTA vascular closure device (VCD; developed for closing large-bore arteriotomies post-transfemoral TAVI) vs the suture-based Prostar XL VCD in terms of safety and feasibility at 30-day follow-up assessed via vascular and bleeding complications and mortality. Overall 168 patients and 198 patients were treated with the MANTA VCD and the Prostar XL VCD, respectively, with successful closure of 98.8% and 98.5%, respectively. Both groups showed similarity with regard to VARC-2 defined as major vascular and bleeding complications. The Prostar XL cohort suffered significantly more frequent minor vascular and bleeding complications. Thirty-day all-cause mortality was estimated to be 2.7%, with no significant variation between the groups. Overall, findings revealed the safety as well as the feasibility of the MANTA device for vascular access closure in patients undergoing transfemoral TAVI.